Modified Vaccinia Ankara virus variant
AssigneeBavarian Nordic A/S
InventorsPaul Chaplin, Paul Howley, Christine Meisinger-Henschel
Life of this patent
Estimating the term…
Abstract
The present invention provides an attenuated virus, which is derived from Modified Vaccinia Ankara virus and characterized by the loss of its capability to reproductively replicate in human cell lines. It further describes recombinant viruses derived from this virus and the use of the virus, or its recombinants, as a medicament or vaccine. A method is provided for inducing an immune response in individuals who may be immune-compromised. In addition, a method is provided for the administration of a therapeutically effective amount of the virus, or its recombinants, in a vaccinia virus prime/vaccinia virus boost inoculation regimen.
Claims21
An isolated Modified Vaccinia Ankara (MVA) virus characterized by having the capability of reproductive replication in vitro in chicken embryo fibroblasts (CEF), but no capability of reproductive replication in vitro in the human keratinocyte cell line HaCaT and the human cervix adenocarcinoma cell line HeLa:
- wherein the isolated MVA virus is generated by:
- (a) introducing a Modified Vaccinia Ankara strain into non-human cells in which the virus is able to reproductively replicate;
- (b) isolating an MVA virus from the infected cells;
- and
- (c) determining that said isolated MVA virus has the capability of reproductive replication in vitro in chicken embryo fibroblasts (CEF), but no capability of reproductive replication in vitro in the human keratinocyte cell line HaCaT and the human cervix adenocarcinoma cell line HeLa.
A method for generating a Modified Vaccinia Ankara (MVA) virus comprising:
- (a) introducing a Modified Vaccinia Ankara strain into non-human cells in which the virus is able to reproductively replicate;
- (b) isolating an MVA virus from the infected cells;
- and
- (c) determining that said isolated MVA virus has capability of reproductive replication in vitro in chicken embryo fibroblasts (CEF), but no capability of reproductive replication in vitro in the human keratinocyte cell line HaCaT and the human cervix adenocarcinoma cell line HeLa.
An isolated Modified Vaccinia Ankara (MVA) virus characterized by having the capability of reproductive replication in vitro in chicken embryo fibroblasts (CEF) and by being more attenuated than MVA-575 in the human keratinocyte cell line HaCaT, in the human bone osteosarcoma cell line 143B, and in the human cervix adenocarcinoma cell line HeLa.
A method for generating a Modified Vaccinia Ankara (MVA) virus comprising:
- (a) introducing a Modified Vaccinia Ankara strain into non-human cells in which the virus is able to reproductively replicate;
- (b) isolating an MVA virus from the infected cells;
- and
- (c) determining that said isolated MVA virus has the capability of reproductive replication in vitro in chicken embryo fibroblasts (CEF), and is more attenuated than MVA-575 in the human keratinocyte cell line HaCaT, in the human bone osteosarcoma cell line 143B, and in the human cervix adenocarcinoma cell line Hela.
Dependencies are inferred from the claim text.